help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
The Role of Hypoxia-Induced Factors in Tumor Progression
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vaupel, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaupel, P.

The Role of Hypoxia-Induced Factors in Tumor Progression

Peter Vaupel

Institute of Physiology and Pathophysiology, University of Mainz, Mainz, Germany

Correspondence: Peter Vaupel, M.D., Dr. Med., M.A., Institute of Physiology and Pathophysiology, University of Mainz, Duesbergweg 6, 55099 Mainz, Germany. Telephone: 49-6131-3925929; Fax: 49-6131-3925774; e-mail: vaupel{at}uni-mainz.de

Hypoxia is a common characteristic of locally advanced solid tumors that has been associated with diminished therapeutic response and, more recently, with malignant progression, that is, an increasing probability of recurrence, locoregional spread, and distant metastasis. Emerging evidence indicates that the effect of hypoxia on malignant progression is mediated by a series of hypoxia-induced proteomic and genomic changes activating angiogenesis, anaerobic metabolism, and other processes that enable tumor cells to survive or escape their oxygendeficient environment. The transcription factor hypoxia-inducible factor 1 (HIF-1) is a major regulator of tumor cell adaptation to hypoxic stress. Tumor cells with proteomic and genomic changes favoring survival under hypoxic conditions will proliferate, thereby further aggravating the hypoxia. The selection and expansion of new (and more aggressive) clones, which eventually become the dominant tumor cell type, lead to the establishment of a vicious circle of hypoxia and malignant progression.

Key Words. Hypoxia • HIF-1{alpha} • Proteome changes • Angiogenesis • Genome changes




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
C-Y Chai, W-T Chen, W-C Hung, W-Y Kang, Y-C Huang, Y-C Su, and C-H Yang
Hypoxia-inducible factor-1{alpha} expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma
J. Clin. Pathol., May 1, 2008; 61(5): 658 - 664.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
P. Vaupel
Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis
Oncologist, May 1, 2008; 13(suppl_3): 21 - 26.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
P. Sonveaux, I. I. Lobysheva, O. Feron, and T. J. McMahon
Transport and Peripheral Bioactivities of Nitrogen Oxides Carried by Red Blood Cell Hemoglobin: Role in Oxygen Delivery
Physiology, April 1, 2007; 22(2): 97 - 112.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
B. Zhou, D. K. Ann, X. Li, K.-J. Kim, H. Lin, P. Minoo, E. D. Crandall, and Z. Borok
Hypertonic induction of aquaporin-5: novel role of hypoxia-inducible factor-1{alpha}
Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1280 - C1290.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
K S Kimbro and J W Simons
Hypoxia-inducible factor-1 in human breast and prostate cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 739 - 749.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Montemurro, M. Donadio, M. Clavarezza, S. Redana, M. E. Jacomuzzi, G. Valabrega, S. Danese, G. Vietti-Ramus, A. Durando, M. Venturini, et al.
Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy.
Oncologist, April 1, 2006; 11(4): 318 - 324.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. H Nelson and C. R Dolder
Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors
Ann. Pharmacother., February 1, 2006; 40(2): 261 - 269.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. O. Ibrahim, T. Hahn, C. Franke, D. P. Stiehl, R. Wirthner, R. H. Wenger, and D. M. Katschinski
Induction of the Hypoxia-Inducible Factor System by Low Levels of Heat Shock Protein 90 Inhibitors
Cancer Res., December 1, 2005; 65(23): 11094 - 11100.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
M. D. Pegram
Molecular Determinants of Trastuzumab Response/Resistance
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159.
[Full Text] [PDF]


Home page
JCOHome page
M. D. Pegram, R. Pietras, A. Bajamonde, P. Klein, and G. Fyfe
Targeted Therapy: Wave of the Future
J. Clin. Oncol., March 10, 2005; 23(8): 1776 - 1781.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ezzat, P. Huang, A. Dackiw, and S. L. Asa
Dual Inhibition of RET and FGFR4 Restrains Medullary Thyroid Cancer Cell Growth
Clin. Cancer Res., February 1, 2005; 11(3): 1336 - 1341.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2004 by AlphaMed Press.